Annals of Hematology

, Volume 91, Issue 2, pp 223–233

Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

  • Young-Woong Won
  • Jung Hye Kwon
  • Soon Il Lee
  • Sung Yong Oh
  • Won Seog Kim
  • Seok Jin Kim
  • Jong-Ho Won
  • Kyoung Ha Kim
  • Seong Kyu Park
  • Jin Seok Kim
  • Cheolwon Suh
  • Dok Hyun Yoon
  • Joon Seong Park
  • Min Kyoung Kim
  • Hawk Kim
  • Hye Jin Kang
  • Yeung-Chul Mun
  • Jae-Yong Kwak
  • Hyo Jung Kim
  • Hyeon-Seok Eom
Original Article

Abstract

Ethnic and regional differences in the epidemiology and pathological aspects of Hodgkin’s lymphoma (HL) between Western and Asian patients may be associated with differences in clinical features and prognosis. We retrospectively analyzed the clinical and histopathological characteristics, therapeutic outcomes, and prognostic factors of 539 HL patients treated at 16 centers in Korea. We found that the incidence of histological subtypes of HL in Korea was similar to that in Western and other Asian countries. However, the incidence peaked between 16 and 30 years of age, unlike the bimodal age distribution seen in Western countries. In patients with stage I–IIA non-bulky disease, the complete response (CR) rate was similar between combined modality therapy and chemotherapy alone (93% vs. 84%, P = 0.44), and there was no difference in relapse-free survival (RFS) and overall survival (OS). Patients with stage I–II disease plus unfavorable factors and those with advanced-stage disease treated with combination chemotherapy regimens had an overall CR rate of 77%, with no difference between doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and non-ABVD regimens (77.2% vs. 76.8%, P = 0.95). Among those patients who achieved final CR, there was no significant difference in RFS or OS between those who achieved interim CR and PR. Only the presence of B symptoms was independently predictive of a shorter RFS. Age > 45 years, Eastern Cooperative Oncology Group 2–4, and B symptoms were independent risk factors for death. Although the incidence of HL was lower in Korea than in Western countries, the distribution of morphological subtypes, treatment outcomes, and patient prognosis were similar.

Keywords

Hodgkin’s lymphoma Treatment Outcome Prognosis 

References

  1. 1.
    Altekruse S, Kosary C, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H. SEER cancer statistics review, 1975–2007. National Cancer Institute, BethesdaGoogle Scholar
  2. 2.
    Kuruvilla J (2009) Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009:497–506CrossRefGoogle Scholar
  3. 3.
    Canellos GP, Niedzwiecki D (2002) Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346:1417–1418PubMedCrossRefGoogle Scholar
  4. 4.
    Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21:607–614PubMedCrossRefGoogle Scholar
  5. 5.
    Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, Koch P, Hanel M, Pfreundschuh M, Wilhelm M, Trumper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Muller-Hermelink HK, Hasenclever D, Loffler M (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548–4554PubMedCrossRefGoogle Scholar
  6. 6.
    Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, Boyle P (2008) Cancer incidence in five continents. International Agency for Research on CancerGoogle Scholar
  7. 7.
    Allemani C, Sant M, De Angelis R, Marcos-Gragera R, Coebergh JW (2006) Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 107:352–360PubMedCrossRefGoogle Scholar
  8. 8.
    Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS (2010) Cancer statistics in Korea: incidence, mortality and survival in 2006–2007. J Korean Med Sci 25:1113–1121PubMedCrossRefGoogle Scholar
  9. 9.
    Mani H, Jaffe ES (2009) Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma 9:206–216PubMedCrossRefGoogle Scholar
  10. 10.
    Carreon JD, Morton LM, Devesa SS, Clarke CA, Gomez SL, Glaser SL, Sakoda LC, Linet MS, Wang SS (2008) Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996–2004. Cancer Causes Control 19:1171–1181PubMedCrossRefGoogle Scholar
  11. 11.
    Wu SJ, Chen CY, Su IJ, Tang JL, Chou WC, Ko BS, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Tien HF (2008) Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. J Formos Med Assoc 107:4–12PubMedCrossRefGoogle Scholar
  12. 12.
    Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Suefuji N, Kikuchi M, Ohshima K (2008) Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int 58:174–182PubMedCrossRefGoogle Scholar
  13. 13.
    Chen WL, Tsai WC, Chao TY, Sheu LF, Chou JM, Kao WY, Chen YC, Ho CL (2010) The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 89:553–562PubMedCrossRefGoogle Scholar
  14. 14.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276PubMedCrossRefGoogle Scholar
  15. 15.
    Yoon SO, Suh C, Lee DH, Chi HS, Park CJ, Jang SS, Shin HR, Park BH, Huh J (2010) Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol 85:760–764PubMedCrossRefGoogle Scholar
  16. 16.
    MacMahon B (1966) Epidemiology of Hodgkin's disease. Cancer Res 26:1189–1201PubMedGoogle Scholar
  17. 17.
    Schnitzer B (2009) Hodgkin lymphoma. Hematol Oncol Clin North Am 23:747–768PubMedCrossRefGoogle Scholar
  18. 18.
    Duhmke E, Franklin J, Pfreundschuh M, Sehlen S, Willich N, Ruhl U, Muller RP, Lukas P, Atzinger A, Paulus U, Lathan B, Ruffer U, Sieber M, Wolf J, Engert A, Georgii A, Staar S, Herrmann R, Beykirch M, Kirchner H, Emminger A, Greil R, Fritsch E, Koch P, Drochtert A, Brosteanu O, Hasenclever D, Loeffler M, Diehl V (2001) Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19:2905–2914PubMedGoogle Scholar
  19. 19.
    Engert A, Plutschow A, Eich H, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn K, Wilhelm M (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640–652PubMedCrossRefGoogle Scholar
  20. 20.
    Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357:1916–1927PubMedCrossRefGoogle Scholar
  21. 21.
    Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640–652PubMedCrossRefGoogle Scholar
  22. 22.
    Canellos GP, Abramson JS, Fisher DC, LaCasce AS (2010) Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 28:1611–1615PubMedCrossRefGoogle Scholar
  23. 23.
    Macdonald DA, Connors JM (2007) New strategies for the treatment of early stages of Hodgkin's lymphoma. Hematol Oncol Clin North Am 21:871–880PubMedCrossRefGoogle Scholar
  24. 24.
    Straus DJ, Portlock CS, Qin J, Myers J, Zelenetz AD, Moskowitz C, Noy A, Goy A, Yahalom J (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104:3483–3489PubMedCrossRefGoogle Scholar
  25. 25.
    Herbst C, Rehan FA, Brillant C, Bohlius J, Skoetz N, Schulz H, Monsef I, Specht L, Engert A (2010) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review. Haematologica 95:494–500PubMedCrossRefGoogle Scholar
  26. 26.
    Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B (1997) Treatment of advanced Hodgkin's disease with chemotherapy–comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15:1638–1645PubMedGoogle Scholar
  27. 27.
    Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM (1998) MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 16:19–26PubMedGoogle Scholar
  28. 28.
    Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P (1996) Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol 14:1421–1430PubMedGoogle Scholar
  29. 29.
    Diehl V, Behringer K (2006) Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma? Cancer Invest 24:461–465PubMedCrossRefGoogle Scholar
  30. 30.
    Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, Burgers JM, Thomas J, Monconduit M, Noordijk EM et al (1991) Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 114:361–365PubMedGoogle Scholar
  31. 31.
    Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630–1636PubMedGoogle Scholar
  32. 32.
    Mauch P, Goodman R, Hellman S (1978) The significance of mediastinal involvement in early stage Hodgkin's disease. Cancer 42:1039–1045PubMedCrossRefGoogle Scholar
  33. 33.
    Tubiana M, Henry-Amar M, Hayat M, Burgers M, Qasim M, Somers R, Sizoo W, Van der Schueren E (1984) Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease. Cancer 54:885–894PubMedCrossRefGoogle Scholar
  34. 34.
    Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506–1514PubMedCrossRefGoogle Scholar
  35. 35.
    Zander T, Wiedenmann S, Wolf J (2002) Prognostic factors in Hodgkin's lymphoma. Ann Oncol 13(Suppl 1):67–74PubMedGoogle Scholar
  36. 36.
    Nogova L, Reineke T, Eich HT, Josting A, Muller-Hermelink HK, Wingbermuhle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Muller RP, Diehl V, Engert A (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683–1687PubMedCrossRefGoogle Scholar
  37. 37.
    Wirth A, Yuen K, Barton M, Roos D, Gogna K, Pratt G, Macleod C, Bydder S, Morgan G, Christie D (2005) Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104:1221–1229PubMedCrossRefGoogle Scholar
  38. 38.
    Maeda LS, Advani RH (2009) The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 21:397–400PubMedCrossRefGoogle Scholar
  39. 39.
    Lee AI, LaCasce AS (2009) Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist 14:739–751PubMedCrossRefGoogle Scholar
  40. 40.
    Biasoli I, Stamatoullas A, Meignin V, Delmer A, Reman O, Morschhauser F, Coiffier B, Bosly A, Divine M, Brice P (2010) Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 116:631–639PubMedCrossRefGoogle Scholar
  41. 41.
    Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon A (2010) Lymphocyte-predominant Hodgkin lymphoma–clinical features and treatment outcomes from a 30-year experience. Ann Oncol 21:2061–2068PubMedCrossRefGoogle Scholar
  42. 42.
    Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, Bredenfeld H, Skripnitchenko R, Muller RP, Muller-Hermelink HK, Diehl V, Engert A (2008) Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434–439PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Young-Woong Won
    • 1
  • Jung Hye Kwon
    • 2
  • Soon Il Lee
    • 3
  • Sung Yong Oh
    • 4
  • Won Seog Kim
    • 5
  • Seok Jin Kim
    • 5
  • Jong-Ho Won
    • 6
  • Kyoung Ha Kim
    • 6
  • Seong Kyu Park
    • 7
  • Jin Seok Kim
    • 8
  • Cheolwon Suh
    • 9
  • Dok Hyun Yoon
    • 9
  • Joon Seong Park
    • 10
  • Min Kyoung Kim
    • 11
  • Hawk Kim
    • 12
  • Hye Jin Kang
    • 13
  • Yeung-Chul Mun
    • 14
  • Jae-Yong Kwak
    • 15
  • Hyo Jung Kim
    • 16
  • Hyeon-Seok Eom
    • 1
  1. 1.Hematology–Oncology Clinic, Research Institute and HospitalNational Cancer CenterGoyang-siRepublic of Korea
  2. 2.Division of Hematology–Oncology, Department of Internal Medicine, Kangdong Sacred Heart HospitalHallym UniversitySeoulRepublic of Korea
  3. 3.Division of Hematology–Oncology, Department of Medicine, Dankook University HospitalDankook UniversityCheonanRepublic of Korea
  4. 4.Department of Internal Medicine, Dong-A University Medical CenterDong-A UniversityBusanRepublic of Korea
  5. 5.Division of Hematology–Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan UniversitySeoulRepublic of Korea
  6. 6.Division of Hematology–Oncology, Department of Internal Medicine, Soonchunhyang University HospitalSoonchunhyang UniversitySeoulRepublic of Korea
  7. 7.Department of Hematology–Oncology, Soonchunhyang University Bucheon HospitalSoonchunhyang UniversityBucheonRepublic of Korea
  8. 8.Department of Internal Medicine, Severance HospitalYonsei UniversitySeoulRepublic of Korea
  9. 9.Department of Oncology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  10. 10.Department of Hematology–Oncology, Ajou University HospitalAjou UniversitySuwonRepublic of Korea
  11. 11.Department of Internal Medicine, Yeungnam University Medical CenterYeungnam UniversityDaeguRepublic of Korea
  12. 12.Division of Hematology–Oncology, Ulsan University HospitalUniversity of UlsanUlsanRepublic of Korea
  13. 13.Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center HospitalKorea Institute of Radiological & Medical SciencesSeoulRepublic of Korea
  14. 14.Division of Hematology–Oncology, Ewha Womans University Mokdong HospitalEwha Womans UniversitySeoulRepublic of Korea
  15. 15.Division of Hematology–Oncology, Department of Internal Medicine, Chonbuk National University HospitalChonbuk National UniversityJeonjuRepublic of Korea
  16. 16.Department of Internal Medicine, Hallym University Sacred Heart HospitalHallym UniversityAnyangRepublic of Korea

Personalised recommendations